You can name the drug. The provision that compliance decks still cite for the opposite proposition was removed from the statute more than a decade ago, and it is worth knowing that before you redesign a funnel around a rule that no longer exists.
Former 21 U.S.C. § 353a(c) read: “A drug may be compounded under subsection (a) of this section only if the pharmacy, licensed pharmacist, or licensed physician does not advertise or promote the compounding of any particular drug, class of drug, or type of drug.” Congress struck that subsection in the Drug Quality and Security Act, Pub. L. 113-54, § 106(a)(2) and (3), enacted November 27, 2013. It followed the Supreme Court’s decision in Thompson v. Western States Medical Center, 535 U.S. 357 (2002), which had held the advertising restrictions unconstitutional.
So the sentence “we cannot say semaglutide because of 503A” is describing repealed law.
What that does not mean
It does not mean the advertising is unregulated. The constraint moved rather than disappeared, and where it moved to is stricter about the thing operators care less about.
| Regime | What it reaches | The practical limit |
|---|---|---|
| FDCA misbranding | False or misleading statements about the drug | Presenting a compounded drug as though it were approved |
| FTC substantiation | Efficacy, safety and results claims | You must hold the evidence before the claim runs |
| State boards | Pharmacy and medical advertising rules | Varies, and some are stricter than federal law |
| Platform policy | What the ad network will accept | Not law, but it is what actually stops the campaign |
The line that draws enforcement
A compounded drug is not an FDA-approved drug. It is not reviewed for safety or efficacy, and it carries no approved labeling. Every serious problem in this category comes from advertising that blurs that, whether by implication or by omission.
Things that cross it:
- Calling the product FDA approved, or letting design imply it with approval-style badges and seals.
- Describing it as “the same as” the reference product. It is a different preparation from a different manufacturer under a different legal regime.
- Importing the reference product’s trial results as though they were your product’s evidence.
- Safety claims that rest on the approved product’s record.
Our fuller treatment of the term itself is at what FDA approved means, and the supply-side history is at compounded GLP-1 after the shortage.
The shortage question sits underneath the ad
Advertising presumes you may lawfully compound and dispense the preparation at all, and that question has moved repeatedly as shortage designations changed. An advertisement is downstream of it. If the sourcing basis is not solid, the cleanest ad copy in the world does not help you, and a campaign that outlives the basis it was built on is its own exposure.
Re-check the basis on a schedule rather than at launch only.
What a defensible ad looks like
- Name the drug if you want to. The statutory bar was repealed. Say what it is.
- Say it is compounded, and say it plainly, in the ad rather than in a footer on a landing page three clicks later.
- Do not claim approval, equivalence or the reference product’s evidence. This is the one that draws letters.
- Hold substantiation for every efficacy or results claim before it runs. See FTC rules for testimonials and influencers for how that interacts with patient stories.
- Check your state’s board rules, which can be stricter than the federal floor and are not preempted by the 2013 repeal.
- Read the platform policy separately. Ad networks apply their own rules and will not be argued out of them with a citation.
What this means for you
Stop designing around a repealed subsection, and start designing around the approval line, which is where the actual exposure sits. Most of the compounded weight-management advertising we see is cautious about the drug’s name and careless about implying approval, which is precisely backwards. Write the copy so a reader finishes it knowing the preparation is compounded and is not an approved product, keep the evidence for anything you assert about results, and re-verify the sourcing basis on a calendar rather than trusting a decision made at launch. If your marketing team is working from a deck that cites 503A’s advertising clause, that deck is at least twelve years out of date and the rest of it deserves a look.
Related reading
Frequently asked questions
Can you advertise compounded semaglutide by name?
Nothing in 503A prohibits it. The subsection that barred advertising the compounding of a particular drug, former 21 U.S.C. § 353a(c), was struck by the Drug Quality and Security Act in 2013, following Thompson v. Western States Medical Center. Other rules still govern what the advertisement may claim.
Did the Supreme Court strike down the compounding advertising ban?
Thompson v. Western States Medical Center, 535 U.S. 357 (2002), held the advertising restrictions unconstitutional. Congress then removed the subsection from the statute in the Drug Quality and Security Act, Pub. L. 113-54, in 2013.
What can I not say about compounded semaglutide?
Anything presenting it as an FDA-approved product, as equivalent to the reference product, or as carrying that product’s safety and efficacy evidence. A compounded preparation is not reviewed for safety or efficacy and has no approved labeling.
Do I have to say the product is compounded?
Saying so plainly, in the advertisement itself, is the practical way to avoid an implication of approval. Disclosure buried on a landing page several clicks from the ad does less work than operators assume.
Do state rules still restrict this advertising?
They can. State pharmacy and medical board advertising rules operate alongside federal law and are sometimes stricter. The 2013 repeal removed a federal condition, not state authority, and advertising platforms apply their own policies on top.
This is general information, not legal advice. Rules vary by state and change. Confirm your own facts with counsel.